Last Friday I received an email with some great news đ The Scientific Advisory Board and the Board of the Hanarth Fonds have decided that 6 candidates are eligible for funding of their proposal. The quality of the proposals was very good and we are happy to inform you that your proposal has been selected…
The Medical Oncologist perspective With great pleasure I chaired the session “What s the future role of artificial intelligence in medical oncology?” at the European Society for Medical Oncology (ESMO) congress 2019. Also good to see so many people attending this session. For those that are interested in the presentation, I provide the presentation here.…
Link to paper Peters MAM, Meijer C, Fehrmann RSN, Walenkamp AME, Kema IP, de Vries EGE, Hollema H, Oosting SF. Abstract In preclinical studies serotonin stimulates and dopamine inhibits tumour growth and angiogenesis. Information regarding serotonin and dopamine receptor (5-HTR and DRD) expression in human cancers is limited. Therefore, we screened a large tumour set…
Today I agreed to take on the role of an associate editor for Cancer Genetics in Frontiers in Genetcs and Frontiers in Oncology. As an Associate Editor, I will actively contribute to the strategic development of the section and ensure its quality through overseeing the review process of manuscripts. This is a nice opportunity for…
Link to paper Bouwstra R, He Y, de Boer JW, Kooistra H, Cendrowicz E, Fehrmann RSN, Ammatuna E, Eulenburg C, Nijland M, Huls G, Bremer E, van Meerten T. Abstract Addition of rituximab (R) to “CHOP” (cyclophosphamide, doxorubicin, vincristine, prednisone) chemotherapy improved outcome for diffuse large B-cell lymphoma (DLBCL) patients. Approximately 40% of patients that…
On Wednesday July 10th, Stephanie van Gijn successfully defended her PhD thesis. We wish her all the best in her new position at the Institut fĂŒr Genetik of the University ZĂŒrich.
Link to paper Venema CM, Bense RD, Steenbruggen TG, Nienhuis HH, Qiu SQ, van Kruchten M, Brown M, Tamimi RM, Hospers GAP, Schröder CP, Fehrmann RSN, de Vries EGE. Abstract The androgen receptor (AR) is a drug target in breast cancer, and AR-targeted therapies have induced tumor responses in breast cancer patients. In this review,…
https://bmccancer.biomedcentral.com/articles/10.1186/s12885-019-5545-0 Rovers KP, Bakkers C, Simkens GAAM, Burger JWA, Nienhuijs SW, Creemers GM, Thijs AMJ, Brandt- Kerkhof ARM, Madsen EVE, Ayez N, de Boer NL, van Meerten E, Tuynman JB, Kusters M, Sluiter NR, Verheul HMW, van der Vliet HJ, Wiezer MJ, Boerma D, Wassenaar ECE, Los M, Hunting CB, Aalbers AGJ, Kok NFM, Kuhlmann…
https://onlinelibrary.wiley.com/doi/abs/10.1002/path.5280 Stutvoet TS, Kol A, de Vries EGE, de Bruyn M, Fehrmann RSN, Terwisscha van Scheltinga AGT, de Jong S. Abstract Immune checkpoint inhibitors targeting programmed cell death protein 1 (PDâ1) and programmed deathâligand 1 (PDâL1) have improved the survival of patients with nonâsmall cell lung cancer (NSCLC). Still, many patients do not respond to…
http://clincancerres.aacrjournals.org/content/early/2019/02/09/1078-0432.CCR-18-2918.long Moek KL, Waaijer SJH, Kok IC, Suurs FV, Brouwers AH, Menke-van der Houven van Oordt CW, Wind TT, Gietema JA, Schröder CP, Mahesh SVK, Jorritsma-Smit A, Lub-de Hooge MN, Fehrmann RSN, de Groot DJ, de Vries EG. ABSTRACTPurpose: Biodistribution of bispecific antibodies in patients is largely unknown. We therefore performed a feasibility study in nine…